Abstract: An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or an —O—C(O)—R? group wherein R and R? independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oil and/or in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oily substance, in which suspens

Abstract: An oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, includes a mixture of platinum complex of general formula I wherein A each independently is an —NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally

Abstract: An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or an —O—C(O)—R? group wherein R and R? independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oil and/or in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oily substance, in which suspens

Abstract: A pharmaceutical composition for administration by injection, comprising a mixture of platinum complex of general formula (I), wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an -0-C(O)—R or -0-C(O)—R? group wherein R and R? independently of one another are a hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group, which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, and of at least one cyclodextrin and/or at least one cyclodextrin derivative, and optionally of at least one pharmaceutically acceptable excipient.

Abstract: The invention relates to a pharmaceutical composition for injectional, in particular targeted local administration, characterized in that it comprises a sterile suspension of platinum complex of general formula (I), wherein A and A? independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B? independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or an —O—C(O)—R? group wherein R and R? independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X? independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X? together form a dicarboxylate group containing 2 to 20 carbon atoms, in a pharmaceutically acceptable hydrophilic or hydrophobic injection liquid phase, 100% of particles of the platinum complex of general formula I being o

Abstract: A pharmaceutical composition for rectal or vaginal application, characterized in that it contains as active substance the platinum complex of general formula wherein A each independently is an —NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and a hydrophilic gel-forming base, comprising gelatin, water and glycerol.

Abstract: An oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, includes a mixture of platinum complex of general formula I wherein A each independently is an —NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally

Abstract: Biodegradable antitumor composition with prolonged release has at least one antitumor agent and a biodegradable oligoester carrier, having a numeric mean relative molecular mass Mn of from 650 to 7,500, a mass mean relative molecular mass Mw from 800 to 10,000 and a glass transition temperature Tg from ?35 to 45° C. The carrier is prepared by polycondensation reaction of polyhydric alcohol containing at least 3 hydroxy groups with at least one aliphatic ?-hydroxy acid in the molar ratio of polyhydric alcohol to aliphatic ?-hydroxy acid of from 0.5:99.5 to 12:88, and is a polyhydric alcohol to the hydroxy groups of which chains created from several molecules of at least one aliphatic ?-hydroxy acid are bound by ester bonds.